Article Details

Janssen submits marketing authorisation to EMA for teclistamab - PMLiVE

Retrieved on: 2022-02-01 18:56:23

Tags for this article:

Click the tags to see associated articles and topics

Janssen submits marketing authorisation to EMA for teclistamab - PMLiVE. View article details on hiswai:

Excerpt

“Today's submission is an important step forward ... for people living with multiple myeloma, where the need for new treatment strategies remains high ...

Article found on: www.pmlive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up